Adlarity, a once-weekly patch has been launched and is now available for adults with mild, moderate, or severe dementia of the Alzheimer type.Adlarity transdermal patch delivers consistent doses of donepezil all along throughout the week.
ADLARITY, approved by the U.S. Food and Drug Administration in March 2022, is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin, enabling a favorable overall gastrointestinal (GI) side effect profile. Donepezil, an acetylcholinesterase inhibitor and the active ingredient in the oral medication Aricept, is the most prescribed Alzheimer's dementia medication.

Patients may be switched by their prescriber from a daily 5 mg or 10 mg dose of oral donepezil directly to the once-weekly ADLARITY, which is available in daily 5 mg or 10 mg transdermal formulations.
"We are thrilled to be launching ADLARITY and feel fortunate for the opportunity to provide patients living with Alzheimer's dementia, their families, and their caregivers a new, innovative way to deliver donepezil in a consistent and well-tolerated option," said Perry Sternberg, President and Chief Executive Officer of Corium.
"The launch of ADLARITY demonstrates the value of Corium's innovative CORPLEX™ technology and our commitment to providing treatment options that address unmet needs for CNS conditions. I want to thank our people, whose tireless commitment made the possibility of helping millions of people in the U.S. living with Alzheimer's disease a reality."
"I can see this weekly patch helping patients and caregivers by providing the ease of a once-weekly treatment with continuous donepezil delivery through the skin," said Lori La Bey, founder of Alzheimer's Speaks, a patient advocacy organization, and caregiver of a family member with Alzheimer's.
ADLARITY became available through wholesalers as of September 19, 2022, and has received first-line formulary coverage for patients with some commercial insurances, with more expected as the year progresses.
Corium is working with the U.S. Centers for Medicare and Medicaid Services toward greater patient accessibility through government- programs, including Medicare Part D, with coverage expected to begin in 2023. Corium is taking a phased approach to launching ADLARITY. As Medicare becomes available, Corium will broaden launch efforts, with a nationwide launch planned for 2023.
Physicians interested in receiving more information or resources can request field representative support via http://www.adlarityhcp.com/. Corium also is supporting patient access to ADLARITY under CoriumCares™, a patient access and support program offering information about access and reimbursement as well as copay assistance for eligible commercially-insured patients. More information is available at http://www.adlarity.com/savings-and-support or (800) 433-4893.
Reference:
Sozio P, Cerasa LS, Marinelli L, Di Stefano A. Transdermal donepezil on the treatment of Alzheimer's disease. Neuropsychiatric Disease and Treatment. 2012 ;8:361-368. DOI: 10.2147/ndt.s16089. PMID: 22942647; PMCID: PMC3428243.